source
- Alnylam cuts TTR franchise guidance, market cap loses $10.8B as shares tumble 28%Alnylam announced a reduction in its full-year revenue outlook for its transthyretin (TTR) franchise, trimming the midpoint by $200 million. The company now projects TTR therapy sales of $4.2 bill…
- Capricor CEO hints at possible lawsuit after FDA panel rejects Duchenne cardiomyopathy therapyAn FDA Cellular, Tissue, and Gene Therapies advisory committee voted 9-3 against recommending Capricor Therapeutics' cell therapy deramiocel for Duchenne muscular dystrophy cardiomyopathy. The pane…